2021
EZH2 Protein Expression in Triple-negative Breast Cancer Treated With Neoadjuvant Chemotherapy: An Exploratory Study of Association With Tumor Response and Prognosis
Fineberg S, Tian X, Makower D, Harigopal M, Lo Y. EZH2 Protein Expression in Triple-negative Breast Cancer Treated With Neoadjuvant Chemotherapy: An Exploratory Study of Association With Tumor Response and Prognosis. Applied Immunohistochemistry & Molecular Morphology 2021, 30: 157-164. PMID: 35262520, DOI: 10.1097/pai.0000000000000998.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerResidual cancer burdenNeoadjuvant chemotherapyEZH2 protein expressionEZH2 expressionBreast cancerHigh-risk triple negative breast cancerLogistic regressionContinuous variablesStratification of outcomesDisease-free survivalProtein expressionTumor-infiltrating lymphocytesHigh EZH2 expressionMultivariable logistic regressionRisk of relapseDevelopment of metastasesLogistic regression analysisPretherapy biopsiesDisease recurrenceMetastatic recurrenceClinicopathologic featuresCancer burdenTumor responseCore biopsy
2018
Androgen receptor expression is a favorable prognostic factor in triple-negative breast cancers
Zuo T, Wilson P, Cicek AF, Harigopal M. Androgen receptor expression is a favorable prognostic factor in triple-negative breast cancers. Human Pathology 2018, 80: 239-245. PMID: 29902579, DOI: 10.1016/j.humpath.2018.06.003.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerDisease-free survivalBasal-like triple-negative breast cancerFavorable prognostic factorAndrogen receptor expressionAR expressionOverall survivalBreast cancerAR positivityPrognostic factorsTumor sizeHistologic gradeReceptor expressionTissue microarrayAR-positive triple-negative breast cancerSubgroups of TNBCAR-negative TNBCLack estrogen receptorBetter overall survivalDose-dependent effectNodal statusWorse prognosisPathologic stagePatient groupProgesterone receptor
2010
Multiplexed Assessment of the Southwest Oncology Group-Directed Intergroup Breast Cancer Trial S9313 by AQUA Shows that Both High and Low Levels of HER2 Are Associated with Poor Outcome
Harigopal M, Barlow WE, Tedeschi G, Porter PL, Yeh IT, Haskell C, Livingston R, Hortobagyi GN, Sledge G, Shapiro C, Ingle JN, Rimm DL, Hayes DF. Multiplexed Assessment of the Southwest Oncology Group-Directed Intergroup Breast Cancer Trial S9313 by AQUA Shows that Both High and Low Levels of HER2 Are Associated with Poor Outcome. American Journal Of Pathology 2010, 176: 1639-1647. PMID: 20150438, PMCID: PMC2843456, DOI: 10.2353/ajpath.2010.090711.Peer-Reviewed Original ResearchConceptsDisease-free survivalEstrogen receptorContinuous variablesSouthwest Oncology GroupAQUA methodAC chemotherapyMenopausal statusNegative patientsOncology GroupNode statusSequential doxorubicinPoor outcomeTumor sizeProgesterone receptorPrognostic informationWorse outcomesTissue biomarkersTissue microarrayBiphasic effectP53 expressionPatientsHER2Low expressersDiagnostic approachMultiplexed assessment
2009
Multiplexed AQUA-based assessment of SWOG 9313 shows prognostic value of continuous ER, PR and HER2 assessment.
Rimm D, Barlow W, Harigopal M, Tedeschi G, Peggy P, Yeh I, Haskell C, Livingston R, Hortobagyi G, Hayes D. Multiplexed AQUA-based assessment of SWOG 9313 shows prognostic value of continuous ER, PR and HER2 assessment. Cancer Research 2009, 69: 704. DOI: 10.1158/0008-5472.sabcs-704.Peer-Reviewed Original ResearchDisease-free survivalEstrogen receptorHER2 expressionWorse disease-free survivalPoor disease-free survivalContinuous variablesLow HER2 expressionPoor prognostic markerBreast cancer casesBreast cancer therapyBi-phasic effectSame slideHazard ratioMenopausal statusNode statusSequential doxorubicinPoor outcomePrognostic valueTumor sizePrognostic informationWorse outcomesPrognostic markerBreast cancerCancer casesTissue microarray
2006
Molecular Classification Identifies a Subset of Human Papillomavirus–Associated Oropharyngeal Cancers With Favorable Prognosis
Weinberger PM, Yu Z, Haffty BG, Kowalski D, Harigopal M, Brandsma J, Sasaki C, Joe J, Camp RL, Rimm DL, Psyrri A. Molecular Classification Identifies a Subset of Human Papillomavirus–Associated Oropharyngeal Cancers With Favorable Prognosis. Journal Of Clinical Oncology 2006, 24: 736-747. PMID: 16401683, DOI: 10.1200/jco.2004.00.3335.Peer-Reviewed Original ResearchConceptsOropharyngeal squamous cell carcinomaHuman papillomavirusFavorable prognosisClass IIILocal recurrencePrognostic valueHuman Papillomavirus–Associated Oropharyngeal CancerHPV DNA presenceHPV16 viral loadDisease-free survivalMultivariable survival analysisSquamous cell carcinomaLong-term patientsThree-class modelReal-time polymerase chain reactionHPV statusLow p53Only patientsOverall survivalOropharyngeal cancerViral loadCell carcinomaPolymerase chain reactionClinical trialsP16 overexpression
2004
Prognostic Significance of p16 Protein Levels in Oropharyngeal Squamous Cell Cancer
Weinberger PM, Yu Z, Haffty BG, Kowalski D, Harigopal M, Sasaki C, Rimm DL, Psyrri A. Prognostic Significance of p16 Protein Levels in Oropharyngeal Squamous Cell Cancer. Clinical Cancer Research 2004, 10: 5684-5691. PMID: 15355894, DOI: 10.1158/1078-0432.ccr-04-0448.Peer-Reviewed Original ResearchConceptsSquamous cell cancerOropharyngeal squamous cell carcinomaOropharyngeal squamous cell cancerDisease-free survivalLocal recurrence rateSquamous cell carcinomaCell cancerOverall survivalRecurrence rateCell carcinomaP16 overexpressionNeck squamous cell cancerLow local recurrence rateAdvanced Tumor-NodeMean patient followIndependent prognostic factorHigh histologic gradeP16 expression statusOverexpression of p16Local recurrencePrognostic factorsPrognostic importanceP16 protein expressionPrognostic significanceHistologic grade